On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...